生物学有效剂量对三叉神经痛伽玛刀术后疼痛缓解与感觉障碍的相关性:一项871例多中心研究
该多中心回顾性研究纳入13个伽玛刀中心871例1型三叉神经痛首次伽玛刀患者,比较生物学有效剂量(BED)与处方剂量对疼痛缓解和感觉障碍的预测价值。结果显示BED≥2100 Gy2.47预测远端靶点30天和1年疼痛缓解,物理剂量≥85 Gy对近端靶点有预测意义,最大脑干点剂量≥29.5 Gy与面部麻木相关。
要点
- BED≥2100 Gy2.47可预测远端靶点30天和1年疼痛缓解,物理剂量≥85 Gy对近端靶点有预测意义。
- 最大脑干点剂量≥29.5 Gy与更高概率的困扰性面部麻木相关。
- 年龄≥63岁与更高的初始疼痛缓解及维持缓解概率相关。
核心结论
- BED和物理剂量均可预测疼痛缓解,可分别作为远端和近端靶点的治疗计划目标,同时考虑将最大脑干点剂量<29.5 Gy作为困扰性麻木的潜在约束。
研究设计与样本
- 回顾性研究,纳入13个伽玛刀中心的871例1型三叉神经痛首次伽玛刀患者,比较BED与处方剂量及其他剂量学因素的预测价值。
主要发现
- 中位年龄68岁,60%为女性;近70%患者疼痛位于V2和/或V3皮节,60%以右侧为主;89.2%为改良BNI疼痛强度量表IV或V级,74.1%服用1或2种止痛药。
- 中位处方剂量80 Gy(范围62.5-95 Gy),77.9%靶向三叉神经近端,中位随访21个月(范围6-156个月)。
- 可评估患者中81.8%在 median 30天出现初始疼痛缓解(改良BNI疼痛强度量表I-IIIa级)。
- 709例初始疼痛缓解患者中,42.3%在中位44个月后至少经历一次疼痛复发,其中49.0%接受第二次手术;25.3%患者在中位8个月后出现新发面部麻木。
- BED≥2100 Gy2.47预测远端靶点30天和1年疼痛缓解,物理剂量≥85 Gy对近端靶点有预测意义,但该亚组BED值范围受限可能是混杂因素;最大脑干点剂量≥29.5 Gy与更高概率的困扰性面部麻木相关。
关键数值与推荐
- BED≥2100 Gy2.47预测远端靶点30天和1年疼痛缓解。
- 物理剂量≥85 Gy对近端靶点有预测意义。
- 最大脑干点剂量≥29.5 Gy与更高概率的困扰性面部麻木相关。
临床怎么用
- 作者认为BED和物理剂量可分别作为远端和近端靶点的治疗计划目标,同时考虑将最大脑干点剂量<29.5 Gy作为困扰性麻木的潜在约束。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recent studies have suggested that biologically effective dose (BED) is an important correlate of pain relief and sensory dysfunction after Gamma Knife radiosurgery (GKRS) for trigeminal neuralgia (TN). The goal of this study was to determine if BED is superior to prescription dose in predicting outcomes in TN patients undergoing GKRS as a first procedure. METHODS: This was a retrospective study of 871 patients with type 1 TN from 13 GKRS centers. Patient demographics, pain characteristics, treatment parameters, and outcomes were reviewed. BED was compared with prescription dose and other dosimetric factors for their predictive value. RESULTS: The median age of the patients was 68 years, and 60% were female. Nearly 70% of patients experienced pain in the V2 and/or V3 dermatomes, predominantly on the right side (60%). Most patients had modified BNI Pain Intensity Scale grade IV or V pain (89.2%) and were taking 1 or 2 pain medications (74.1%). The median prescription dose was 80 Gy (range 62.5-95 Gy). The proximal trigeminal nerve was targeted in 77.9% of cases, and the median follow-up was 21 months (range 6-156 months). Initial pain relief (modified BNI Pain Intensity Scale grades I-IIIa) was noted in 81.8% of evaluable patients at a median of 30 days. Of 709 patients who achieved initial pain relief, 42.3% experienced at least one pain recurrence after GKRS at a median of 44 months, with 49.0% of these patients undergoing a second procedure. New-onset facial numbness occurred in 25.3% of patients after a median of 8 months. Age ≥ 63 years was associated with a higher probability of both initial pain relief and maintaining pain relief. A distal target location was associated with a higher probability of initial and long-term pain relief, but also a higher incidence of sensory dysfunction. BED ≥ 2100 Gy2.47 was predictive of pain relief at 30 days and 1 year for the distal target, whereas physical dose ≥ 85 Gy was significant for the proximal target, but the restricted range of BED values in this subgroup could be a confounding factor. A maximum brainstem point dose ≥ 29.5 Gy was associated with a higher probability of bothersome facial numbness. CONCLUSIONS: BED and physical dose were both predictive of pain relief and could be used as treatment planning goals for distal and proximal targets, respectively, while considering maximum brainstem point dose < 29.5 Gy as a potential constraint for bothersome numbness.
引用
- Warnick RE, Paddick I, Mathieu D, et al. The relevance of biologically effective dose for pain relief and sensory dysfunction after Gamma Knife radiosurgery for trigeminal neuralgia: an 871-patient multicenter study. J Neurosurg. 2024. PMID: 38364220. doi:10.3171/2023.12.JNS231569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。